Prodotti GS / Area HIV
Gilead Submits Lenacapavir New Drug Application (NDA) to FDA (USA)
![Immagine News](/media/0icnkhat/cat-1.jpg?center=0.55476190476190479,0.25&mode=crop&width=722&height=442)
Gilead has submitted on 28 June 2021 a New Drug Application (NDA) to the U.S. Food and Drug Administration for lenacapavir, an investigational, long-acting agent in development for the treatment of HIV in people living with HIV who are heavily treatment-experienced. If approved, lenacapavir would be the first and the only HIV treatment option administered every six months.
Grazie per il tuo feedback!